Important Notice on Mounjaro for Weight Loss
Please note that consultations regarding the use of Mounjaro (Tirzepatide) for weight loss are not part of our NHS services. Any discussions or prescriptions related to this use must be arranged with a private provider. Thank you for your understanding. Please see below for the local NHS position on this medication:
POSITION STATEMENT (Lancashire & South Cumbria Medicines Management Group
Mounjaro® (tirzepatide) for managing overweight and Obesity in primary care
Updated May 2025
Recommendation:
Mounjaro® (Tirzepatide) for managing overweight and Obesity in primary care – LSCMMG RAG status ‘Do Not Prescribe’
Please note: Do not prescribe in primary care until further notice and refrain from referring to specialist weight management services until Commissioning pathways have been clarified by the ICB.
It is expected that the RAG position will be updated periodically and in line with the implementation plan.
NHSE published an update in March 2025 outlining the implementation plan of NICE TA 1026, addressing the challenges and strategies for integrating this treatment into NHS services.1
NHS England recognises the resource and cost impact of NICE TA 1026 and intends to provide additional funding to ICBs to support with:
- Medication costs related to prescribing Obesity treatments [GLP-1s and GIP/GLP-1s] across all care settings for NHS England's prioritised patient cohort only; and,
- Management costs related to prescribing weight management services in a primary care setting.
As the intention is to centrally arrange wrap-around care during 2025/26, NHS England will retain funding for these services, which will be made available at no cost to ICBs.
References
1.
Interim Commissioning guidance: implementation of the NICE technology appraisal TA1026 and the NICE funding variation for tirzepatide (Mounjaro®) for the management of obesity. Accessed via: https://www.england.nhs.uk/publication/interim-commissioning-guidance-implementation-of-the-nice-technology-appraisal-ta1026-and-the-nice-funding-variation-for-tirzepatide-mounjaro-for-the-management-of-obesity/ (accessed online 16/4/25)